The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 17, 2021

Filed:

Jan. 09, 2020
Applicant:

Oregon Health & Science University, Portland, OR (US);

Inventors:

Klaus Frueh, Portland, OR (US);

Louis Picker, Portland, OR (US);

Scott Hansen, Portland, OR (US);

Jonah Sacha, Beaverton, OR (US);

Daniel Malouli, Hillsboro, OR (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 9/02 (2006.01); C12Q 1/68 (2018.01); C12N 15/00 (2006.01); A61K 39/12 (2006.01); A61K 35/17 (2015.01); A61K 39/21 (2006.01); A61K 39/245 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 35/17 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); A61K 39/245 (2013.01); C12N 7/00 (2013.01); C12N 9/0093 (2013.01); C12N 15/00 (2013.01); C12Q 1/68 (2013.01); C12Y 117/04001 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16143 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); Y02A 50/30 (2018.01);
Abstract

Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.


Find Patent Forward Citations

Loading…